Share Price and Basic Stock Data
Last Updated: November 20, 2025, 8:53 pm
| PEG Ratio | -1.06 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Trigyn Technologies Ltd operates in the IT Consulting and Software sector, with a current market capitalization of ₹218 Cr and a share price of ₹71.3. The company has shown fluctuating revenue trends over the past quarters, recording sales of ₹285.27 Cr in June 2022, which increased to ₹339.78 Cr by December 2022. However, sales experienced a decline to ₹306.90 Cr by December 2023, followed by a projected recovery to ₹334.14 Cr in March 2024. Over the fiscal years, Trigyn reported sales of ₹1,273 Cr for FY 2023, slightly increasing to ₹1,280 Cr in FY 2024 before declining to ₹898 Cr in FY 2025. This decline reflects challenges in maintaining consistent revenue growth, with total revenue for the trailing twelve months (TTM) standing at ₹879 Cr. The company’s operating profit margin (OPM) has also been precarious, with a recent negative margin of -1.07% indicating operational inefficiencies that need addressing.
Profitability and Efficiency Metrics
Trigyn Technologies has faced significant profitability challenges, as evidenced by its reported net profit of ₹-22.02 Cr in December 2023 and a meager ₹12 Cr in FY 2025. The operating profit margin has declined consistently, with the most recent figure at -1.07%, highlighting operational inefficiencies. The company’s return on equity (ROE) stood at 1.72%, while return on capital employed (ROCE) was recorded at 4.17%. Both metrics are considerably low compared to typical sector standards, indicating that Trigyn is not utilizing its equity and capital effectively. The interest coverage ratio (ICR) is strong at 12.76x, suggesting that Trigyn can comfortably meet its interest obligations, despite the poor profitability metrics. However, the negative operating profit in many quarters, particularly in December 2023 and June 2025, raises concerns about the sustainability of its business model.
Balance Sheet Strength and Financial Ratios
Trigyn’s balance sheet reflects a solid equity capital base of ₹31 Cr, with total reserves increasing to ₹710 Cr as of FY 2025. The company’s borrowings are low at ₹13 Cr, indicating a conservative approach to debt management. The price-to-book value (P/BV) ratio of 0.28x suggests that the stock is undervalued compared to its book value, which stands at ₹240.71 per share. The current ratio is robust at 4.82, indicating a strong liquidity position to cover short-term liabilities. However, the asset turnover ratio has declined to 1.01, reflecting a decrease in operational efficiency in generating revenue from its assets. The financial ratios indicate a mixed picture: while liquidity is strong, the low profitability ratios and operational inefficiencies pose risks to the overall financial health of the company.
Shareholding Pattern and Investor Confidence
As of March 2025, Trigyn Technologies has a diverse shareholding structure, with promoters holding 44.51% of the shares, while institutional investors like foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold negligible stakes of 0.22% and 0.01%, respectively. The public holds a significant 55.35% stake, reflecting a broad base of retail investor participation. However, the decline in the number of shareholders from 38,413 in December 2022 to 34,157 in March 2025 raises concerns about investor confidence. The lack of institutional interest may suggest a cautious outlook from professional investors regarding the company’s performance and potential for recovery. This shareholding pattern indicates a reliance on retail investors, which can lead to volatility in stock performance, particularly in challenging market conditions.
Outlook, Risks, and Final Insight
The outlook for Trigyn Technologies is contingent on its ability to stabilize its revenue and improve profitability. The company faces risks including operational inefficiencies reflected in its negative OPM and declining net profits, which could deter potential investors. Additionally, the low institutional ownership could limit the stock’s upward potential. However, strengths such as a strong liquidity position and low debt levels provide a buffer against economic downturns. The company must focus on enhancing operational efficiencies and restoring investor confidence to improve its market position. If it can successfully navigate these challenges, Trigyn may leverage its substantial reserves to invest in growth initiatives, potentially leading to a turnaround in its financial performance. The key will be executing a strategic plan that addresses its operational weaknesses while capitalizing on its strong balance sheet.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Trigyn Technologies Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Naapbooks Ltd | 160 Cr. | 148 | 194/99.8 | 24.4 | 36.4 | 0.00 % | 23.6 % | 17.1 % | 10.0 |
| IB Infotech Enterprises Ltd | 27.9 Cr. | 218 | 310/140 | 19.9 | 26.7 | 0.46 % | 38.5 % | 35.4 % | 10.0 |
| Hit Kit Global Solutions Ltd | 5.52 Cr. | 1.13 | 1.73/0.91 | 2.47 | 0.00 % | 2.14 % | 2.15 % | 2.00 | |
| Globalspace Technologies Ltd | 57.4 Cr. | 16.7 | 25.0/13.7 | 103 | 15.8 | 0.00 % | 2.13 % | 1.41 % | 10.0 |
| First Fintec Ltd | 7.09 Cr. | 6.82 | 11.7/5.25 | 88.6 | 10.3 | 0.00 % | 0.28 % | 0.85 % | 10.0 |
| Industry Average | 20,256.89 Cr | 585.07 | 92.12 | 126.08 | 0.55% | 14.93% | 20.42% | 6.95 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 285.27 | 323.64 | 339.78 | 324.04 | 322.50 | 316.12 | 306.90 | 334.14 | 241.94 | 207.81 | 206.78 | 239.66 | 224.50 |
| Expenses | 272.16 | 306.53 | 317.16 | 316.07 | 304.80 | 299.96 | 323.41 | 316.78 | 232.47 | 203.92 | 207.41 | 234.15 | 226.91 |
| Operating Profit | 13.11 | 17.11 | 22.62 | 7.97 | 17.70 | 16.16 | -16.51 | 17.36 | 9.47 | 3.89 | -0.63 | 5.51 | -2.41 |
| OPM % | 4.60% | 5.29% | 6.66% | 2.46% | 5.49% | 5.11% | -5.38% | 5.20% | 3.91% | 1.87% | -0.30% | 2.30% | -1.07% |
| Other Income | 0.51 | 1.27 | 2.47 | 2.23 | 3.21 | 3.10 | 2.42 | 3.26 | 4.00 | 3.65 | 4.40 | 3.96 | 4.28 |
| Interest | 0.70 | 0.53 | 0.54 | 0.47 | 0.42 | 0.38 | 0.33 | 0.53 | 0.33 | 0.27 | 0.29 | 1.88 | 0.54 |
| Depreciation | 1.65 | 1.67 | 1.70 | 1.78 | 1.67 | 1.58 | 1.55 | 2.07 | 1.27 | 1.47 | 1.03 | 1.24 | 0.78 |
| Profit before tax | 11.27 | 16.18 | 22.85 | 7.95 | 18.82 | 17.30 | -15.97 | 18.02 | 11.87 | 5.80 | 2.45 | 6.35 | 0.55 |
| Tax % | 47.20% | 33.19% | 32.87% | 67.42% | 35.76% | 37.17% | 37.88% | -5.33% | 35.89% | 93.79% | 49.80% | 59.69% | 940.00% |
| Net Profit | 5.94 | 10.81 | 15.34 | 2.59 | 12.09 | 10.86 | -22.02 | 18.98 | 7.61 | 0.36 | 1.23 | 2.56 | -4.61 |
| EPS in Rs | 1.93 | 3.51 | 4.98 | 0.84 | 3.93 | 3.53 | -7.15 | 6.17 | 2.47 | 0.12 | 0.40 | 0.83 | -1.50 |
Last Updated: August 20, 2025, 2:00 am
Below is a detailed analysis of the quarterly data for Trigyn Technologies Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 224.50 Cr.. The value appears to be declining and may need further review. It has decreased from 239.66 Cr. (Mar 2025) to 224.50 Cr., marking a decrease of 15.16 Cr..
- For Expenses, as of Jun 2025, the value is 226.91 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 234.15 Cr. (Mar 2025) to 226.91 Cr., marking a decrease of 7.24 Cr..
- For Operating Profit, as of Jun 2025, the value is -2.41 Cr.. The value appears to be declining and may need further review. It has decreased from 5.51 Cr. (Mar 2025) to -2.41 Cr., marking a decrease of 7.92 Cr..
- For OPM %, as of Jun 2025, the value is -1.07%. The value appears to be declining and may need further review. It has decreased from 2.30% (Mar 2025) to -1.07%, marking a decrease of 3.37%.
- For Other Income, as of Jun 2025, the value is 4.28 Cr.. The value appears strong and on an upward trend. It has increased from 3.96 Cr. (Mar 2025) to 4.28 Cr., marking an increase of 0.32 Cr..
- For Interest, as of Jun 2025, the value is 0.54 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.88 Cr. (Mar 2025) to 0.54 Cr., marking a decrease of 1.34 Cr..
- For Depreciation, as of Jun 2025, the value is 0.78 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.24 Cr. (Mar 2025) to 0.78 Cr., marking a decrease of 0.46 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.55 Cr.. The value appears to be declining and may need further review. It has decreased from 6.35 Cr. (Mar 2025) to 0.55 Cr., marking a decrease of 5.80 Cr..
- For Tax %, as of Jun 2025, the value is 940.00%. The value appears to be increasing, which may not be favorable. It has increased from 59.69% (Mar 2025) to 940.00%, marking an increase of 880.31%.
- For Net Profit, as of Jun 2025, the value is -4.61 Cr.. The value appears to be declining and may need further review. It has decreased from 2.56 Cr. (Mar 2025) to -4.61 Cr., marking a decrease of 7.17 Cr..
- For EPS in Rs, as of Jun 2025, the value is -1.50. The value appears to be declining and may need further review. It has decreased from 0.83 (Mar 2025) to -1.50, marking a decrease of 2.33.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:14 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 451 | 492 | 625 | 679 | 685 | 895 | 911 | 985 | 1,041 | 1,273 | 1,280 | 898 | 879 |
| Expenses | 407 | 456 | 563 | 612 | 623 | 810 | 833 | 893 | 975 | 1,212 | 1,245 | 880 | 872 |
| Operating Profit | 44 | 36 | 62 | 67 | 61 | 85 | 77 | 92 | 65 | 61 | 35 | 18 | 6 |
| OPM % | 10% | 7% | 10% | 10% | 9% | 9% | 8% | 9% | 6% | 5% | 3% | 2% | 1% |
| Other Income | 56 | 5 | 2 | 1 | 1 | -4 | 5 | 3 | 3 | 6 | 12 | 17 | 16 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 2 | 2 | 3 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 7 | 7 | 7 | 5 | 5 |
| Profit before tax | 98 | 40 | 62 | 66 | 60 | 78 | 78 | 89 | 59 | 58 | 38 | 26 | 15 |
| Tax % | 18% | 39% | 38% | 41% | 34% | 38% | 36% | 30% | 34% | 40% | 48% | 56% | |
| Net Profit | 81 | 24 | 38 | 39 | 39 | 48 | 50 | 62 | 39 | 35 | 20 | 12 | -0 |
| EPS in Rs | 27.49 | 8.32 | 13.02 | 13.13 | 13.20 | 15.74 | 16.27 | 20.19 | 12.69 | 11.26 | 6.48 | 3.82 | -0.15 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 5% | 2% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -70.37% | 58.33% | 2.63% | 0.00% | 23.08% | 4.17% | 24.00% | -37.10% | -10.26% | -42.86% | -40.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 128.70% | -55.70% | -2.63% | 23.08% | -18.91% | 19.83% | -61.10% | 26.84% | -32.60% | 2.86% |
Trigyn Technologies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 0% |
| 3 Years: | -5% |
| TTM: | -27% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -5% |
| 5 Years: | -23% |
| 3 Years: | -30% |
| TTM: | -99% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 8% |
| 3 Years: | -10% |
| 1 Year: | -36% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 5% |
| 3 Years: | 3% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 1:50 pm
Balance Sheet
Last Updated: June 16, 2025, 11:10 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 29 | 29 | 29 | 30 | 30 | 31 | 31 | 31 | 31 | 31 | 31 | 31 |
| Reserves | 193 | 218 | 260 | 297 | 341 | 403 | 473 | 527 | 577 | 650 | 670 | 710 |
| Borrowings | 0 | 0 | 0 | 0 | 1 | 8 | 6 | 10 | 7 | 7 | 5 | 13 |
| Other Liabilities | 49 | 51 | 57 | 58 | 75 | 100 | 108 | 115 | 140 | 168 | 168 | 150 |
| Total Liabilities | 271 | 299 | 347 | 385 | 446 | 541 | 618 | 683 | 755 | 856 | 874 | 903 |
| Fixed Assets | 92 | 91 | 88 | 89 | 90 | 90 | 100 | 99 | 108 | 107 | 103 | 97 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 0 | 0 |
| Investments | 0 | 0 | 1 | 1 | 1 | 4 | 4 | 5 | 21 | 83 | 17 | 38 |
| Other Assets | 179 | 207 | 258 | 295 | 355 | 447 | 513 | 577 | 624 | 665 | 755 | 769 |
| Total Assets | 271 | 299 | 347 | 385 | 446 | 541 | 618 | 683 | 755 | 856 | 874 | 903 |
Below is a detailed analysis of the balance sheet data for Trigyn Technologies Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 31.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 31.00 Cr..
- For Reserves, as of Mar 2025, the value is 710.00 Cr.. The value appears strong and on an upward trend. It has increased from 670.00 Cr. (Mar 2024) to 710.00 Cr., marking an increase of 40.00 Cr..
- For Borrowings, as of Mar 2025, the value is 13.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 5.00 Cr. (Mar 2024) to 13.00 Cr., marking an increase of 8.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 150.00 Cr.. The value appears to be improving (decreasing). It has decreased from 168.00 Cr. (Mar 2024) to 150.00 Cr., marking a decrease of 18.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 903.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 874.00 Cr. (Mar 2024) to 903.00 Cr., marking an increase of 29.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 97.00 Cr.. The value appears to be declining and may need further review. It has decreased from 103.00 Cr. (Mar 2024) to 97.00 Cr., marking a decrease of 6.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 38.00 Cr.. The value appears strong and on an upward trend. It has increased from 17.00 Cr. (Mar 2024) to 38.00 Cr., marking an increase of 21.00 Cr..
- For Other Assets, as of Mar 2025, the value is 769.00 Cr.. The value appears strong and on an upward trend. It has increased from 755.00 Cr. (Mar 2024) to 769.00 Cr., marking an increase of 14.00 Cr..
- For Total Assets, as of Mar 2025, the value is 903.00 Cr.. The value appears strong and on an upward trend. It has increased from 874.00 Cr. (Mar 2024) to 903.00 Cr., marking an increase of 29.00 Cr..
Notably, the Reserves (710.00 Cr.) exceed the Borrowings (13.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 44.00 | 36.00 | 62.00 | 67.00 | 60.00 | 77.00 | 71.00 | 82.00 | 58.00 | 54.00 | 30.00 | 5.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 105 | 114 | 83 | 68 | 74 | 79 | 104 | 89 | 99 | 87 | 71 | 99 |
| Inventory Days | 9 | |||||||||||
| Days Payable | 407 | |||||||||||
| Cash Conversion Cycle | 105 | 114 | 83 | 68 | 74 | -319 | 104 | 89 | 99 | 87 | 71 | 99 |
| Working Capital Days | 75 | 82 | 57 | 42 | 50 | 62 | 71 | 56 | 57 | 72 | 53 | 64 |
| ROCE % | 29% | 17% | 24% | 22% | 17% | 21% | 17% | 17% | 10% | 9% | 6% | 4% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 3.82 | 6.48 | 11.26 | 12.69 | 20.20 |
| Diluted EPS (Rs.) | 3.82 | 6.48 | 11.26 | 12.69 | 20.11 |
| Cash EPS (Rs.) | 5.45 | 8.72 | 13.47 | 14.87 | 21.20 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 240.71 | 227.77 | 221.21 | 197.37 | 181.30 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 240.71 | 227.77 | 221.21 | 197.37 | 181.30 |
| Revenue From Operations / Share (Rs.) | 291.71 | 415.67 | 413.41 | 338.01 | 320.09 |
| PBDIT / Share (Rs.) | 11.51 | 15.18 | 21.85 | 22.18 | 30.80 |
| PBIT / Share (Rs.) | 9.88 | 12.95 | 19.64 | 20.01 | 29.79 |
| PBT / Share (Rs.) | 8.60 | 12.41 | 18.92 | 19.11 | 28.91 |
| Net Profit / Share (Rs.) | 3.82 | 6.48 | 11.26 | 12.69 | 20.20 |
| NP After MI And SOA / Share (Rs.) | 3.82 | 6.48 | 11.26 | 12.69 | 20.20 |
| PBDIT Margin (%) | 3.94 | 3.65 | 5.28 | 6.56 | 9.62 |
| PBIT Margin (%) | 3.38 | 3.11 | 4.75 | 5.91 | 9.30 |
| PBT Margin (%) | 2.94 | 2.98 | 4.57 | 5.65 | 9.03 |
| Net Profit Margin (%) | 1.31 | 1.56 | 2.72 | 3.75 | 6.30 |
| NP After MI And SOA Margin (%) | 1.31 | 1.56 | 2.72 | 3.75 | 6.30 |
| Return on Networth / Equity (%) | 1.58 | 2.84 | 5.09 | 6.43 | 11.13 |
| Return on Capital Employeed (%) | 4.03 | 5.58 | 8.73 | 10.01 | 16.14 |
| Return On Assets (%) | 1.30 | 2.28 | 4.05 | 5.17 | 9.10 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Total Debt / Equity (X) | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 |
| Asset Turnover Ratio (%) | 1.01 | 1.48 | 1.58 | 0.20 | 0.20 |
| Current Ratio (X) | 4.82 | 4.26 | 3.36 | 3.69 | 4.02 |
| Quick Ratio (X) | 4.76 | 4.21 | 3.30 | 3.67 | 3.99 |
| Inventory Turnover Ratio (X) | 109.49 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 12.76 | 28.21 | 30.01 | 24.69 | 34.91 |
| Interest Coverage Ratio (Post Tax) (X) | 5.66 | 13.05 | 16.47 | 15.12 | 23.89 |
| Enterprise Value (Cr.) | -195.88 | -48.38 | 147.35 | 204.15 | 3.24 |
| EV / Net Operating Revenue (X) | -0.21 | -0.03 | 0.11 | 0.19 | 0.00 |
| EV / EBITDA (X) | -5.53 | -1.03 | 2.19 | 2.99 | 0.03 |
| MarketCap / Net Operating Revenue (X) | 0.23 | 0.22 | 0.22 | 0.39 | 0.19 |
| Price / BV (X) | 0.28 | 0.41 | 0.41 | 0.68 | 0.34 |
| Price / Net Operating Revenue (X) | 0.23 | 0.22 | 0.22 | 0.39 | 0.19 |
| EarningsYield | 0.05 | 0.06 | 0.12 | 0.09 | 0.32 |
After reviewing the key financial ratios for Trigyn Technologies Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 3.82. This value is below the healthy minimum of 5. It has decreased from 6.48 (Mar 24) to 3.82, marking a decrease of 2.66.
- For Diluted EPS (Rs.), as of Mar 25, the value is 3.82. This value is below the healthy minimum of 5. It has decreased from 6.48 (Mar 24) to 3.82, marking a decrease of 2.66.
- For Cash EPS (Rs.), as of Mar 25, the value is 5.45. This value is within the healthy range. It has decreased from 8.72 (Mar 24) to 5.45, marking a decrease of 3.27.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 240.71. It has increased from 227.77 (Mar 24) to 240.71, marking an increase of 12.94.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 240.71. It has increased from 227.77 (Mar 24) to 240.71, marking an increase of 12.94.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 291.71. It has decreased from 415.67 (Mar 24) to 291.71, marking a decrease of 123.96.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 11.51. This value is within the healthy range. It has decreased from 15.18 (Mar 24) to 11.51, marking a decrease of 3.67.
- For PBIT / Share (Rs.), as of Mar 25, the value is 9.88. This value is within the healthy range. It has decreased from 12.95 (Mar 24) to 9.88, marking a decrease of 3.07.
- For PBT / Share (Rs.), as of Mar 25, the value is 8.60. This value is within the healthy range. It has decreased from 12.41 (Mar 24) to 8.60, marking a decrease of 3.81.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 3.82. This value is within the healthy range. It has decreased from 6.48 (Mar 24) to 3.82, marking a decrease of 2.66.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 3.82. This value is within the healthy range. It has decreased from 6.48 (Mar 24) to 3.82, marking a decrease of 2.66.
- For PBDIT Margin (%), as of Mar 25, the value is 3.94. This value is below the healthy minimum of 10. It has increased from 3.65 (Mar 24) to 3.94, marking an increase of 0.29.
- For PBIT Margin (%), as of Mar 25, the value is 3.38. This value is below the healthy minimum of 10. It has increased from 3.11 (Mar 24) to 3.38, marking an increase of 0.27.
- For PBT Margin (%), as of Mar 25, the value is 2.94. This value is below the healthy minimum of 10. It has decreased from 2.98 (Mar 24) to 2.94, marking a decrease of 0.04.
- For Net Profit Margin (%), as of Mar 25, the value is 1.31. This value is below the healthy minimum of 5. It has decreased from 1.56 (Mar 24) to 1.31, marking a decrease of 0.25.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.31. This value is below the healthy minimum of 8. It has decreased from 1.56 (Mar 24) to 1.31, marking a decrease of 0.25.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.58. This value is below the healthy minimum of 15. It has decreased from 2.84 (Mar 24) to 1.58, marking a decrease of 1.26.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.03. This value is below the healthy minimum of 10. It has decreased from 5.58 (Mar 24) to 4.03, marking a decrease of 1.55.
- For Return On Assets (%), as of Mar 25, the value is 1.30. This value is below the healthy minimum of 5. It has decreased from 2.28 (Mar 24) to 1.30, marking a decrease of 0.98.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.01. It has decreased from 1.48 (Mar 24) to 1.01, marking a decrease of 0.47.
- For Current Ratio (X), as of Mar 25, the value is 4.82. This value exceeds the healthy maximum of 3. It has increased from 4.26 (Mar 24) to 4.82, marking an increase of 0.56.
- For Quick Ratio (X), as of Mar 25, the value is 4.76. This value exceeds the healthy maximum of 2. It has increased from 4.21 (Mar 24) to 4.76, marking an increase of 0.55.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 109.49. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 109.49, marking an increase of 109.49.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 12.76. This value is within the healthy range. It has decreased from 28.21 (Mar 24) to 12.76, marking a decrease of 15.45.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.66. This value is within the healthy range. It has decreased from 13.05 (Mar 24) to 5.66, marking a decrease of 7.39.
- For Enterprise Value (Cr.), as of Mar 25, the value is -195.88. It has decreased from -48.38 (Mar 24) to -195.88, marking a decrease of 147.50.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is -0.21. This value is below the healthy minimum of 1. It has decreased from -0.03 (Mar 24) to -0.21, marking a decrease of 0.18.
- For EV / EBITDA (X), as of Mar 25, the value is -5.53. This value is below the healthy minimum of 5. It has decreased from -1.03 (Mar 24) to -5.53, marking a decrease of 4.50.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 1. It has increased from 0.22 (Mar 24) to 0.23, marking an increase of 0.01.
- For Price / BV (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.41 (Mar 24) to 0.28, marking a decrease of 0.13.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 1. It has increased from 0.22 (Mar 24) to 0.23, marking an increase of 0.01.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to 0.05, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Trigyn Technologies Ltd:
- Net Profit Margin: 1.31%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.03% (Industry Average ROCE: 14.93%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.58% (Industry Average ROE: 20.42%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.66
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.76
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 43.3 (Industry average Stock P/E: 92.12)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.31%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| IT Consulting & Software | Unit 27, SDF 1, Mumbai Maharashtra 400096 | ro@trigyn.com http://www.trigyn.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Satyam Cherukuri | Chairman & Non-Exe.Director |
| Ms. P Bhavana Rao | Executive Director |
| Mr. R Ganapathi | Non Executive Director |
| Dr. P Raja Mohan Rao | Non Executive Director |
| Ms. Lakshmi Potluri | Independent Director |
| Mr. Ishwar Halalli | Independent Director |
| Mr. Syed Ahmed Sultan | Independent Director |
| Mr. Vijay Mallya | Independent Director |
FAQ
What is the intrinsic value of Trigyn Technologies Ltd?
Trigyn Technologies Ltd's intrinsic value (as of 21 November 2025) is 150.11 which is 110.53% higher the current market price of 71.30, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 218 Cr. market cap, FY2025-2026 high/low of 124/60.0, reserves of ₹710 Cr, and liabilities of 903 Cr.
What is the Market Cap of Trigyn Technologies Ltd?
The Market Cap of Trigyn Technologies Ltd is 218 Cr..
What is the current Stock Price of Trigyn Technologies Ltd as on 21 November 2025?
The current stock price of Trigyn Technologies Ltd as on 21 November 2025 is 71.3.
What is the High / Low of Trigyn Technologies Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Trigyn Technologies Ltd stocks is 124/60.0.
What is the Stock P/E of Trigyn Technologies Ltd?
The Stock P/E of Trigyn Technologies Ltd is 43.3.
What is the Book Value of Trigyn Technologies Ltd?
The Book Value of Trigyn Technologies Ltd is 247.
What is the Dividend Yield of Trigyn Technologies Ltd?
The Dividend Yield of Trigyn Technologies Ltd is 0.00 %.
What is the ROCE of Trigyn Technologies Ltd?
The ROCE of Trigyn Technologies Ltd is 4.17 %.
What is the ROE of Trigyn Technologies Ltd?
The ROE of Trigyn Technologies Ltd is 1.72 %.
What is the Face Value of Trigyn Technologies Ltd?
The Face Value of Trigyn Technologies Ltd is 10.0.